Original ArticleImproving paclitaxel pharmacokinetics by using tumor-specific mesoporous silica nanoparticles with intraperitoneal delivery
Graphical Abstract
Mesoporous silica nanoparticles (MSNs) containing paclitaxel facilitated its selective tumor accumulation and increased retention time both in the peritoneal cavity and in the systemic circulation. The pharmacokinetics and distribution profiles of paclitaxel were improved for the effective treatment for peritoneal cancers.
Section snippets
Materials
Paclitaxel (PTX), cephalomannine, rhodamine, mesoporous silica type MCM-41, tetraethyl orthosilicate (TEOS), trypsin-EDTA solution, Triton X-100, and Dulbecco's modified Eagle's medium (DMEM) were purchased from Sigma (St. Louis, MO, USA). 1,1′-Dioctadecyl-3 ,3 ,3′,3′-tetramethylindotricarbocyanine iodide (DiR), Fetal Bovine Serum (FBS), and penicillin–streptomycin solution were purchased from Biotium (Invitrogen, USA). All other chemicals were of analytical grade.
Synthesis of mesoporous silica nanoparticles
MSNs were synthesized as
Synthesis and characterization of mesoporous silica nanoparticles (MSNs)
Transmission electron microscopy analysis showed that the synthesized MSNs were spherical in shape and approximately 100 nm in diameter with pores in hexagonal arrays (Figure 1). The pore size of the synthesized MSNs is 2.3 ± 0.3 nm, with narrow distribution. These MSNs tend to aggregate and settle in aqueous due to high density of the silica material (~ 2 g/cm3) and the hydrophobic surface. After sonication, the particles can be homogenously suspended. The measured particle size using dynamic light
Discussion
The present study was designed to demonstrate the positive impact of MSN on the disposition of paclitaxel in IP chemotherapy. According to our prior report, the MSNs accumulated preferentially in tumors with limited exposure to other tissues after IP delivery of radioactive MSNs.11 We report here that paclitaxel carried by MSNs exhibited a sustained release profile from MSNs compared to paclitaxel only. The relatively slow and sustained release from PTX-loaded MSNs may be ascribed to the strong
References (28)
- et al.
Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy
J Control Release
(2015) - et al.
Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest
Gynecol Oncol
(2000) - et al.
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study
Gynecol Oncol
(2006) - et al.
The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes
Biomaterials
(2013) - et al.
Successfully tailoring the pore size of mesoporous silica nanoparticles: exploitation of delivery systems for poorly water-soluble drugs
Int J Pharm
(2012) - et al.
Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation
Int J Pharm
(2007) - et al.
Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration
J Pharm Sci
(1985) - et al.
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study
J Clin Oncol
(1992) - et al.
Effect of maceligan on the systemic exposure of paclitaxel: in vitro and in vivo evaluation
Eur J Pharm Sci
(2010) - et al.
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
N Engl J Med
(1996)
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
N Engl J Med
Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study
J Natl Cancer Inst
A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies
Cancer Chemother Pharmacol
Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models
J Control Release
Cited by (50)
Delivery of paclitaxel by carboxymethyl chitosan-functionalized dendritic fibrous nano-silica: Fabrication, characterization, controlled release performance and pharmacokinetics
2024, International Journal of Biological MacromoleculesRelease kinetics approach of stimuli-responsive mesoporous silica nanocarriers: pH-sensitive linker versus pH-sensitive framework
2024, Journal of Drug Delivery Science and TechnologyTreatment of Alzheimer's disease by microcapsule regulates neurotransmitter release via microfluidic technology
2023, Engineered RegenerationOvercoming drug resistance with a docetaxel and disulfiram loaded pH-sensitive nanoparticle
2023, Journal of Controlled ReleaseEngineering biodegradable periodic mesoporous functionalized-organosilica nanocarriers for efficient paclitaxel delivery
2023, Colloids and Surfaces A: Physicochemical and Engineering AspectsCitation Excerpt :Mesoporous silica nanoparticles (MSN) have been widely utilized as a promising drug delivery system for various biomedical applications owing to their controllable morphology and particle size, ease of functional surface modification, large surface area, and tunable pore size which contribute to the high loading capacity and high stability of drugs [1].
Nanocarriers for targeted drug delivery
2021, Journal of Drug Delivery Science and TechnologyCitation Excerpt :These early tests give solid confirmation that MSNs are promising candidates for enhanced tumor treatment and that they can diminish reactions for normal tissues and cells. Table 2 enlists applications of various types of NPs [108–120]. Clinically used nanomedicines and those in various trial phases are given in Table 3.
The work is supported by National Cancer Institute (NCI)R03CA184394 and the Research Scholar Grant, RSG-15-011-01-CDD from the American Cancer Society.